LBA3 Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer
作者
Julien Hadoux,Rossella Elisei,Marcia S. Brose,Ana O. Hoff,Bruce G. Robinson,Ming Gao,Barbara Jarząb,Pavel A. Isaev,Kateřina Kopečková,Jonathan Wadsley,Dagmar Führer,Bhumsuk Keam,Eric Jeffrey Sherman,Makoto Tahara,Mimi I-Nan Hu,Yong Lin,Patricia Maeda,Lori J. Wirth,Jaume Capdevila